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Available online xxxxThe role of insulin-degrading enzyme (IDE), a metalloprotease with high afﬁnity for insulin, in insulin clearance
remains poorly understood. OBJECTIVE: This study aimed to clarify whether IDE is a major mediator of insulin
clearance, and to deﬁne its role in the etiology of hepatic insulin resistance.
Methods:Wegeneratedmicewith liver-speciﬁc deletion of Ide (L-IDE-KO) and assessed insulin clearance and action.
Results: L-IDE-KO mice exhibited higher (~20%) fasting and non-fasting plasma glucose levels, glucose intolerance
and insulin resistance. This phenotype was associated with ~30% lower plasma membrane insulin receptor levels
in liver, aswell as ~55% reduction in insulin-stimulated phosphorylation of the insulin receptor, and its downstream
signaling molecules, AKT1 and AKT2 (reduced by ~40%). In addition, FoxO1 was aberrantly distributed in cellular
nuclei, in parallelwith up-regulationof the gluconeogenic genes Pck1 andG6pc. Surprisingly, L-IDE-KOmice showed
similar plasma insulin levels and hepatic insulin clearance as control mice, despite reduced phosphorylation of the
carcinoembryonic antigen-related cell adhesion molecule 1, which upon its insulin-stimulated phosphorylation,
promotes receptor-mediated insulin uptake to be degraded.
Conclusion: IDE is not a rate-limiting regulator of plasma insulin levels in vivo.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
Insulin-degrading enzyme
Hepatic insulin resistance
Insulin receptor
Carcinoembryonic antigen-related cell adhe-
sion molecule 11. Introduction
Insulin-degrading enzyme (IDE) is a 110-kDa zinc-
metalloendopeptidase ﬁrst identiﬁed and named based on its ability to
bind to and degrade insulin [1]. IDE also degrades several other
intermediate-sized (b80 amino acids) bioactive peptides, including gluca-
gon, amylin and the amyloid β-protein [2]. IDE is ubiquitously expressed
at varying levels in both insulin-responsive and -nonresponsive cell types.
Subcellularly, the protease is primarily cytosolic, but it has been reported
to existwithin anumber of intracellular vesicles, and organelles, aswell as
being associated with membranes, and secreted into the extracellular
space [1,3–6]. This wide distribution suggests a dynamic and multifunc-
tional role for IDE.cultad de Ciencias de la Salud,
adores s/n (Antiguo Hospital
. This is an open access article underBecause IDE has a high afﬁnity for insulin (KM = ~100 nM), it has
been proposed as the major enzyme responsible for its catabolism
[3,7]. In vivo, insulin is produced and secreted by pancreatic β-cells,
which is delivered through the portal venous system to the liver,
where it is primarily cleared, although kidneys and other tissues also
degrade the hormone [1]. In ﬁrst-pass transit, the liver removes ~50%
of circulating insulin. Although the detailed molecular mechanisms of
hepatic insulin clearance are not fully understood, insulin uptake and
intracellular degradation is a receptor-mediated process that occurs
after the binding of the hormone to its receptor (IR) [8]. The insulin-
IR complex is endocytosed via clathrin-coated vesicles and is primarily
delivered to endosomes. In the acidic milieu of the endosomes, insulin
dissociates from the IR, at which point insulin is believed to be de-
graded by IDE, and the receptor is recycled back to the plasma mem-
brane [1]. In recent years, a role for the carcinoembryonic antigen-
related cell adhesion molecule 1 (CEACAM1) in promoting receptor-
mediated insulin uptake has emerged [9]. Upon its phosphorylation
by the receptor, CEACAM1 binds to and increases the rate of thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Analysis of IDE expression in WT and L-IDE-KO mice. (A) Expression of Ide mRNA
in 3-month-old male L-IDE-KO and control littermates. Expression levels are mean ±
SEM. n = 4 per genotype. *p value b0.05 vs. WT by Students' t-test. (B) Hepatic IDE
protein levels in WT, L-IDE-KO, and IDE-KO mice. Representative western blots of liver
lysates (40 μg protein/sample) isolated from 3-month-old WT, L-IDE-KO, and IDE-KO
mice using anti-IDE and anti-actin antibodies. n = 2 per genotype.
2 P. Villa-Pérez et al. / Metabolism Clinical and Experimental 88 (2018) 1–11insulin-receptor complex uptake to be targeted to the cellular degra-
dation pathways, contributing to the regulation of systemic insulin
concentrations [10].
The physiological role of IDE in insulin clearance in vivo began to be
clariﬁedwith the study of micewith global null mutation of Ide (IDE-KO
mice). Consistent with a functional role for IDE in hepatic insulin
clearance, IDE-KO mice exhibit chronic hyperinsulinemia resulting
from impaired insulin clearance [11,12]. They also exhibit marked
glucose intolerance and insulin resistance [11,12]. These results spurred
the notion that transient and/or partial inhibition of IDEmay represent a
new pharmacological approach against type 2 diabetes (T2DM)
[11,13,14]. However, pharmacological inhibition of IDE in mice caused
contradictory observations regarding glucose homeostasis [15–17].
Furthermore, genetic polymorphisms within or near the Ide locus
have been linked to increased, rather than decreased, risk for T2DM
[18–22].
Therefore, the role of IDE in insulin clearance, and how this may
modulate insulin resistance remain to be clariﬁed. To address these
questions, we ablated Ide expression exclusively in hepatocytes, the
major site of insulin clearance, and investigated its effect on insulin
clearance and action.
2. Material and Methods
2.1. Mice Generation and Genotyping
Mice were fed standard rodent chow diet and water ad libitum
in ventilated cages under a 12:12-h light-dark cycle at the animal
facility of the University of Valladolid (UVa). L-IDE-KO mice were
generated from crosses between the B6.Cg-Tg(Alb-cre)21Mgn/J
mouse (Alb-Cre mouse (The Jackson Laboratory, USA) that ex-
presses Cre recombinase cDNA from the mouse albumin (Alb) pro-
moter [23], and the Ide ﬂox/ﬂox mouse on the C57BL/6 J (B6)
background (from Dr. Malcolm A. Leissring, University of California,
Irvine). This mouse has loxP sites ﬂanking exon 3 of the Ide gene. Cre
recombinase-mediated deletion of exon 3 causes a frameshift with
two stop codons in exon 4 and early termination of translation.
Twenty-three independent cohorts (males and females) of the F3
generation were used for metabolic studies and tissue collection.
The IDE-KO mice were kindly provided by Dr. Malcolm A. Leissring
[11]. The Animal Care and Use Committee of the UVa approved all
experiments (protocol #5003931).
The Alb-Cre+ controlmice did not showabnormalmetabolic pheno-
type relative to the C57BL/6J mice that were used in backcrossing. As
Supplementary Table 1 reveals, Alb-Cre+ controlsmanifested compara-
ble body weight and visceral obesity to that of C57BL/6J, in addition to
normoinsulinemia and normal insulin clearance (measured by steady-
state molar ratio of C-peptide/insulin levels). These control mice also
showed normal insulin and glucose tolerance by comparison to
C57BL/6J mice (Supplementary Fig. 1). Thus, we only used Ide ﬂox/ﬂox;
+/+ as wildtype (WT) controls in these studies.
Mice genotyping was performed using genomic DNA isolated from
mouse tail as described previously [24], followed by three PCRs to
amplify: gapdh, Ide and Alb-Cre genes. Breeding strategy and genotyp-
ing of mice are detailed in the Supplementary Experimental
Procedures.
2.2. Plasma Biochemistry
Fasting (16 h) and non-fasting (fed ad libitum) blood glucose and
plasma triglycerides levels were assessed as described previously [24].
Plasma mouse insulin and glucagon levels were assessed using human
or mouse enzyme-linked immunosorbent (ELISA) assays following the
manufacturer's instructions (Mercodia, Sweden). Plasma amylin (Phoe-
nix Pharmaceutical, USA) and amyloid (Aβ40) (Invitrogen, USA) levelsby ELISA assays following the manufacturer's instructions. Plasma C-
peptide levels were assessed by ELISA (ALPCO, USA).
2.3. Hepatic Triglycerides and Glycogen Levels
Hepatic triglyceride contentwas assessed as described previously by
Perdomo et al. [25]. Liver glycogen content was assessed using the Gly-
cogen Assay Kit (Sigma-Aldrich, USA). Brieﬂy, liver samples (10 mg)
were homogenized in 100 μL of water supplemented with protease
and phosphatase inhibitor cocktails (Sigma-Aldrich, USA) on ice.
Homogenates were boiled at 100 °C for 5 min to inactivate enzymes
and centrifuged 5 min at 12300 ×g at room temperature to remove in-
solublematerials. Homogenates were diluted 1:100 in hydrolysis buffer
up to a ﬁnal volume of 50 μL and mixed with 2 μL of Hydrolysis Enzyme
Mix for 30 min at room temperature. Glycogen concentration was de-
termined by a coupled enzyme assay, which yields a colorimetric
(570 nm) product, proportional to the glycogen present in the
homogenate.
2.4. Metabolic Studies
To evaluate alterations in glucose homeostasis in vivo,we performed
intraperitoneal glucose tolerance tests (IP-GTTs) and insulin tolerance
tests (IP-ITTs) as described previously [26]. In vivo plasma insulin clear-
ance was performed as described by Ahrén et al. [27] with some modi-
ﬁcations. Brieﬂy, 3-month-old mice were fasted for 2 h, then
anesthetized using a solution of medetomidine plus ketamine at
0,125 mg/100 g body weight. Afterwards, human insulin (Humulin;
Lilly, USA) was injected intra-orbitally at 1 nmol/kg and blood samples
were collected from the tail vein 0, 5, 10, 20, 30 and 60min after insulin
administration. Plasma human insulin levels were quantiﬁed using a
human ELISA kit (Mercodia, Sweden) following the manufacturer's
instructions.
2.5. Quantitative Real-time PCR
Total RNA from homogenizedmouse tissues was isolated using Trizol
Reagent (Sigma-Aldrich, USA) following the manufacturer's protocol.
After DNAse treatment 500–1000 ng of RNA was used to synthesize
3P. Villa-Pérez et al. / Metabolism Clinical and Experimental 88 (2018) 1–11cDNAwith the Transcriptor First Strand cDNA Synthesis Kit (Roche, USA).
mRNA levels were determined by real time qPCR with TaqMan® probe-
based assays on a Rotor-Gene 3000 instrument (Corbett Research)
using the 2−ΔΔCt relative quantiﬁcation method [28]. TaqMan® Gene Ex-
pression assay references (from Applied Biosystems, USA) were as fol-
lows: Mm00473077_m1 for Ide, Mm01247058_m1 for
phosphoenolpyruvate carboxykinase (Pck1), Mm00839363_m1 for
glucose-6 phosphatase (G6pc), Mm01211875_m1for insulin receptor
(Insr), and Mm00802831_m1 for insulin-like growth factor-1 receptor
(Igf1r). Expression data were normalized to the level of the housekeeping
gene of the ribosomal protein L18 (RPL18; Forward: 5′-AAGACTGCCGT
GGTTGTGG-3′; Reverse: 5′-AGCCTTGAGGATGCGACTC-3′; Probe: 5′-
FAM-TTCCCAAGCTGAAGGTGTGTGCA-BHQ1–3′).2.6. Western Blot Analysis
Western blot analyses on isolated mouse tissues, and subcellular lo-
calization of FoxO1 are detailed in the Supplementary Experimental Pro-
cedures. Rabbit anti-FoxO1 antibody was used as described by Qu et al.
[29]. For co-immunoprecipitation experiments, polyclonal antibodies
against Shc (B-9) was used to immunoprecipitate proteins from tissue
lysates as previously described [30,31].A
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Fig. 2.Metabolic features of L-IDE-KO mice. Fasting (A) and non-fasting (B) blood glucose lev
genotype. *p value b 0.05 vs. WT by Students' t-test. Fasting (C) and non-fasting (D) body w
intake (E). Data are mean ± SEM. n= 5–6 per genotype.2.7. Analysis of β-Cell Function, Pancreatic Histology
and Histomorphometry
To asses β-cell function,micewere fasted overnight followed by an i.
p. injection of a bolus of glucose. Blood sampleswere drawn, and plasma
insulin levels were measured during 30 min. as described above. After-
wards,micewere euthanized and pancreata dissected,ﬁxed in 10% neu-
tral buffer formalin, parafﬁn embedded, and sectioned as described
previously [32]. For islets histomorphometry, sections were stained
with anti-insulin antibody (Abcam, UK). β-cell mass, β-cell area, the
number of islets, and the mean islets size were quantitated using the
ImageJ software (NIH, USA) as described previously [32].2.8. Statistical Analyses
Statistical analysis of data was performed using Prism v. 6.0
(GraphPad Software). Distributions were checked with the
Kolmogorov-Smirnov test. Data are presented as means ± SEM. Com-
parisons between two groups were done using the unpaired Students'
t-test. Comparisons between more than two groups were done using
the one-way ANOVA (Bonferroni test for post-hoc analyses). Differ-
ences were considered signiﬁcant at p b 0.05.B
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Fig. 3. L-IDE-KOmice exhibit impaired glucose homeostasis and insulin resistance. (A) IP-GTT of 3-month-oldmalemice. Data aremean± SEM. n= 12–13 per genotype. *p value b 0.05
vs. WT by Students' t-test. (B) Area under the curve of the IP-GTT. *p value b 0.05 vs. WT by Students' t-test. (C) IP-ITT of 3-month-old male mice. Data are mean ± SEM. n = 12–13 per
genotype. *p value b 0.05 vs.WT by Students' t-test. (D)Area under the curve of the IP-ITT. *p value b 0.05 vs. WT by Students' t-test. (E) Lack of effect of liver-speciﬁc IDE deletion on AKT
signaling in skeletal muscle. Representative western blots depicting basal and insulin-stimulated p-AKT levels in skeletal muscle. Grouping of images from different parts of the same gel
have been used for theﬁnal arrangement of theﬁgure (see Supplementary Fig. 4 for full blots). (F)Densitometric analysis of Ser-473-Akt phosphorylation. The y-axis represents the ratio of
phosphorylated versus total protein in arbitrary units. Data are mean ± SEM. n= 6 per genotype. *p value b0.05 vs. saline treatment by ANOVA.
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3.1. Generation andMolecular Characterization of Liver-speciﬁc IDE Knock-
out Mice
3-month-old male and female Ideﬂox/ﬂox;+/+ mice (henceforth,
wildtype-WT) and Ideﬂox/ﬂox;Alb-Cre/+ (L-IDE-KO) mice were studied.
Hepatic IdemRNA (Fig. 1A) and protein levels (Fig. 1B) were decreased
by ~90–100% in L-IDE-KOmice, compared to controls. No differences in
IDE expressionwere observed in other tissues, except for a ~20% reduc-
tion in IdemRNA levels without changes in IDE protein levels in skeletal
muscle (data not shown). Considering that hepatocytes make up ~85%
of liver cells, it is likely that the minimal amount of IDE detected in
liver of L-IDE-KO mice reﬂects residual expression from
nonparenchymal liver cells (sinusoidal cells, endothelial, Kupffer cells,
etc.) As expected, IDE-KO mice did not express IDE protein in the liver
(Fig. 1B).Fig. 4.Hepatic ablation of Ide does not alter plasma insulin levels and hepatic insulin clearance. F
mice. Data are mean± SEM. n= 12 per genotype. (C) Plasma insulin clearance in 3-month-old
in vivo insulin clearance. (E) Fasting plasma C-peptide levels in 3-month-oldmice fasted overnig
in 3-month-oldmice. Data aremean± SEM. n=10–13 per genotype. (G) Insulin clearancewas
Data are mean ± SEM. n = 6–12 per genotype. (H) Non-fasting plasma glucagon levels in 3
genotype. n.s.; nonstatistical signiﬁcance. (I) Fasting plasma glucagon levels in 3-month-old
nonstatistical signiﬁcance. (J) Fasting plasma amylin levels in 3-month-old male L-IDE-KO and
Aβ40 levels in 3-month-old male L-IDE-KO and control littermates. Data are mean ± SEM. n =3.2. Hepatic IDE Deletion Leads to Glucose Intolerance and Insulin
Resistance, but without Altered Insulin Metabolism
At 3 months of age, male (Fig. 2A–B) and female (Supplementary
Fig. 2A–B) L-IDE-KO mice showed higher fasting and non-fasting
blood glucose levels, as compared toWT controls. These changes in glu-
cose homeostasis were not correlated with an increase in body weight
(Fig. 2C–D and Supplementary Fig. 2C–D) or food intake (Fig. 2E). Con-
sistentwith this metabolic phenotype, L-IDE-KOmice exhibited glucose
intolerance and insulin resistance (Fig. 3A–D and Supplementary Fig. 3).
The insulin resistance observed in L-IDE-KO mice was not correlated
with blunted insulin-signaling in the skeletalmuscle, as shown by intact
phosphorylation of protein kinase B (PKB; AKT1) in response to insulin
(Fig. 3E–F).
Typically, insulin resistance is associated with hyperinsulinemia, but
surprisingly, fasting and non-fasting plasma insulin levels were similar
between L-IDE-KO and control mice (Fig. 4A–B; Supplementary Fig.asting (A) andnon-fasting (B)plasma insulin levels in 3-month-oldmaleWTand L-IDE-KO
male mice. Data are mean± SEM. n=9–6 per genotype. (D) Area under the curve of the
ht. Data aremean±SEM. n=6–12per genotype. (F)Non-fasting plasma C-peptide levels
calculated as themolar ratio of C-peptide to insulin in 3-month-oldmice fasted overnight.
-month-old male L-IDE-KO and control littermates. Data are mean ± SEM. n = 6–9 per
male L-IDE-KO and control littermates. Data are mean ± SEM. n = 9 per genotype. n.s.;
control littermates. Data are mean ± SEM. n = 10–14 per genotype. (K) Fasting plasma
10–15 per genotype.
A B
C D
Pl
as
m
a 
in
su
lin
 le
v
el
s
(n
g/m
L)
WT L-IDE KO
0.0
0.1
0.2
0.3
0.4 Fasting
Pl
as
m
a 
in
su
lin
 le
v
el
s
(n
g/m
L)
WT L-IDE KO
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.6
2.0 Non-Fasting
Time (min) 
H
um
an
 In
su
lin
 (m
U/
L)
0 10 20 30 40 50 60
0
5
10
15
20
WT
L-IDE KO
AU
C 
(A
rb
itr
ar
y 
Un
its
)
WT L-IDE KO
0
100
200
300
400
E
C-
pe
pt
id
e 
(p
M)
WT L-IDE KO
0.0
0.2
0.4
0.6
0.8
Fasting Non-fasting
F
C-
pe
pt
id
e 
(p
M)
WT L-IDE KO
0
1000
2000
3000
4000
G
C-
pe
pt
id
e/
in
su
lin
m
o
la
r r
at
io
WT L-IDE KO
0
10
20
30
40
50
H
JI
K
n.s.
n.s.
G
lu
ca
go
n 
(p
mo
l/L
)
WT L-IDE KO
0
2
4
6
8
10 Non-fasting
G
lu
ca
go
n 
(p
mo
l/L
)
WT L-IDE KO
0
2
4
6
8 Fasting
A
m
yl
in
 (n
g/m
L)
WT L-IDE KO
0.0
0.5
1.0
1.5
2.0 Fasting
Fasting
A
β-4
0 
(p
g/m
L)
WT L-IDE KO
0
20
40
60
80
100
5P. Villa-Pérez et al. / Metabolism Clinical and Experimental 88 (2018) 1–11
p-
IR
β /
 IR
β (
A
.U
.)
0
5
10
15
20
25
*
*
#
IR
β /
 N
a+
/K
+-
AT
Pa
se
 (A
.U
.)
0.0
0.5
1.0
1.5 #
&
p-
A
K
T1
(S
er
47
3)
 / 
A
K
T1
 (A
.U
.)
0
2
4
6
*
* #
p-
A
K
T2
(S
er
47
4)
 / 
A
K
T2
 (A
.U
.)
0
2
4
6
*
*
#
p-
C
EA
C
A
M
1 
/ C
EA
C
A
M
1 
(A
.U
.)
0
5
10
15
20 * #
B
A
Insulin - +
WT
- +
L-IDE-KO
Insulin - +
WT
- +
L-IDE-KO
IG
F-
IR
 / 
N
a+
/K
+  -
AT
Pa
se
 (A
.U
.)
0.0
0.5
1.0
1.5
2.0
C
6 P. Villa-Pérez et al. / Metabolism Clinical and Experimental 88 (2018) 1–11
7P. Villa-Pérez et al. / Metabolism Clinical and Experimental 88 (2018) 1–115A–B). These ﬁndings cast doubt on the notion that IDE is the principal
protease regulating insulin catabolism in vivo [11], and that plasma in-
sulin clearance depends on the protease activity of IDE in the liver [1]. To
directly assess the role of IDE in hepatic insulin clearance, we performed
an in vivo plasma insulin clearance assay. As shown in Fig. 4C–D,male L-
IDE-KO mice (and female, Supplementary Fig. 5C–D) exhibited similar
rates of plasma insulin clearance as controls. Likewise, insulin clearance
measured as steady-state C-peptide/insulinmolar ratio [10] was similar
between L-IDE-KO and WT controls (Fig. 4E–G).
Like insulin, plasma glucagon, amylin and Aβ40 levels remained un-
changed in L-IDE-KO as compared to WT controls (Fig. 4H–K).3.3. IDE Is Necessary for Hepatic Insulin Signaling
To help elucidate the molecular basis underlying the insulin resis-
tance observed in L-IDE-KO mice, we analyzed multiple components
of the intracellular insulin-signaling pathway in liver tissue, a key
organ involved in the regulation of whole-body glucose homeostasis.
To this end, 3-month-oldmale L-IDE-KOandWTmicewere fasted over-
night, then administered an intraperitoneal injection of a bolus of insu-
lin (0.75 U/kg) or saline solution. Ten minutes later, mice were
euthanized, and tissues were dissected.
Hepatic Ide deletion resulted in a mild (~30%) but signiﬁcant reduc-
tion of IR protein level in the plasmamembrane fractions from L-IDE-KO
livers, as demonstrated by Western blot analysis (Fig. 5A-B). Further-
more, its insulin-stimulated phosphorylation was reduced by ~55% in
L-IDE-KO mice, compared to controls (Fig. 5A–B). Consequently,
insulin-stimulated phosphorylation of its substrate, CEACAM1, was
completely abolished despite no change of its hepatic basal expression
by Ide deletion (Fig. 5A-B).
Because L-IDE-KOmicemanifested amarked reduction of CEACAM1
phosphorylation in response to insulin, we hypothesized that it would
be associated with changes in the internalization of the complex
insulin-IR-CEACAM1. To address this question, we carried out co-
immunoprecipitation experiments to detect whether deleting Ide af-
fects insulin-stimulated association between Shc and CEACAM1, a criti-
cal step in the insulin's internalization process [30,33,34]. As Fig. 5C
shows, immunoblotting the Shc immunopellet with CEACAM1 antibody
indicated 1.5-fold increase in the Shc/CEACAM1 binding in response to
insulin in the controls but not the IDE null mice.
On the other hand, the insulin-like growth factor-1 receptor (IGF-IR)
exhibits 70% homology to IR, and in response to insulin shares some of
the signaling pathways with the IR. Western blot analyses revealed
that hepatic Ide deletion did not reduce IGF-IR protein levels in the
plasma membrane fractions from L-IDE-KO livers (Fig. 5A-B). Likewise,
Insr and Igf1rmRNA levelswere similar betweenWT and L-IDE-KOmice
in fasting and non-fasting conditions (Supplementary Fig. 7). Taken to-
gether, these results support the notion that hepatic Ide ablation alters
posttranslational events of the IR in L-IDE-KO mice without affecting
the related IGF-IR.
To further analyze downstream effects of hepatic IDE depletion on
insulin signaling, we examined AKT1 and AKT2 phosphorylation in
total liver lysates. AKT1 phosphorylation, which is chieﬂy involved in
cell survival, protein synthesis and inhibition of apoptosis, and AKT2
phosphorylation, which is exclusively involved in metabolism, were
both reduced, exhibiting signiﬁcant reductions of ~40–45% (Fig. 5A-B).Fig. 5. Hepatic Ide deﬁciency causes multiple changes to intracellular insulin-signaling pa
phosphorylated IR, IGF-IR, CEACAM1, AKT1 and AKT2 levels. Expression of actin and Na+/K+-
from liver membrane fractions (insulin receptor) respectively. Grouping of images from diff
Supplementary Fig. 6 for full blots). (B) Densitometric analyses of the data in panel A. The y-a
mean ± SEM. n = 6 per genotype and condition. *p value b0.05 vs. saline treatment by ANO
b0.05 WT-insulin vs. L-IDE-KO-insulin treatment by ANOVA. (C) Co-immunoprecipitation of C
jected to immunoprecipitation with α-Shc followed by immunoblotting with α-CEACAM1 an
identical results. Lower panel, densitometric analysis of n= 3 independent experiments. *p val3.4. Hepatic Ablation of IDE Causes Up-regulation of Gluconeogenic Genes
A hallmark of hepatic insulin resistance is augmented production of
glucose. The forkhead box O1 (FoxO1) is a nuclear transcription factor
downstream of AKT that integrates insulin signaling with gluconeogen-
esis in the liver, by upregulating the expression of the gluconeogenic
genes Pck1 and G6pc [29]. In response to insulin, FoxO1 is phosphory-
lated, resulting in its nuclear exclusion and inhibition of Pck1 and G6pc
gene expression. Hepatic insulin resistance reduces FoxO1 phosphory-
lation, which results in unleashed gluconeogenesis [35]. To determine
whether the increased blood glucose levels observed in L-IDE-KO mice
were associated with activation of gluconeogenesis, we prepared cyto-
plasmic and nuclear fractions of liver tissues from WT and L-IDE-KO
mice treated with saline or insulin for 10 min. As shown in Fig. 6A,
FoxO1 proteins were detected predominantly in the cytoplasmic frac-
tions after stimulation with insulin in WT mice. In contrast, in L-IDE-
KO mice, FoxO1 underwent a substantial subcellular redistribution,
shifting from the cytoplasmic fraction to thenuclear fraction upon expo-
sure to insulin (Fig. 6A). This was correlated with up-regulation of Pck1
and G6pcmRNA expression levels under either fasting or non-fasting
conditions (Fig. 6B–C).
In addition to FoxO1, AKT phosphorylates and deactivates glycogen
synthase kinase 3 (GSK-3), leading to activation of glycogen synthase
(GS) and thus, inducing glycogen synthesis [36]. To examine the effect
of IDE depletion on glycogenesis, we quantiﬁed phosphorylation levels
of GSK-3 from WT and L-IDE-KO mice treated with saline or insulin
for 10 min. As Fig. 6D revels, insulin-mediated AKT phosphorylation in-
activates GSK-3, which in turn restores GS activity and glycogen synthe-
sis in WT mice. Unexpectedly, relative to WT mice, basal GSK-3
phosphorylation was 3.5-fold higher in L-IDE-KO mice and, moreover,
insulin treatment failed to result in increased phosphorylation
(Fig. 6D). To explore the functional impact of these perturbations, we
analyzed glycogen levels in L-IDE-KO and WT livers. Surprisingly, he-
patic Ide ablation had no effect on liver glycogen levels, under either
fasting (Fig. 6E) or non-fasting (Fig. 6F) conditions. Taken together,
this suggests that Ide deﬁciency in liver must result in other, as-yet un-
identiﬁed mechanisms that compensate for the lack of the expected ef-
fect of AKT on GSK-3 phosphorylation and hepatic glycogen content.
Because insulin also regulates hepatic lipid metabolism via an AKT2
phosphorylation-dependent mechanism [37], we then assessed triglyc-
erides levels in the plasma and livers of 3-month-oldWT and L-IDE-KO
male mice. Hepatic triglyceride content remained similar between WT
and L-IDE-KOmice under either fasting (Fig. 6G) and non-fasting condi-
tions (Fig. 6H). Similarly, circulating plasma triglycerides levels were
comparable in both mouse groups regardless of the feeding status
(Fig. 6I-J).
3.5. β-Cell Function and Histomorphometry in the L-IDE-KO Mice
To asses β-cell function, we monitored plasma insulin levels follow-
ing an i.p. glucose injection after an overnight fasting period in WT and
L-IDE-KO mice. As Fig. 7A-B shows, plasma insulin levels during IP-GTT
were similar between WT and L-IDE-KO mice. Consistently, fasting and
non-fasting plasma C-peptide levels remained unchanged between L-
IDE-KO mice and littermate controls (Fig. 4E–F). In addition, we have
assessed β-cell mass and the number of islets by histomorphometry in
WT and L-IDE-KO mice. As shown in Fig. 7C–F, β-cell mass, β-cell area,thways. (A) Representative Western blots depicting the effects of insulin on total and
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genotypes. Taken together these results indicate that β-cell function
and mass are comparable in L-IDE-KO mice and WT mice.
4. Discussion
Using a mouse harboring liver-speciﬁc ablation of Ide, we show for
the ﬁrst time that hepatic deﬁciency of Ide does not result in
hyperinsulinemia, as expected from deleting a protein that has been
postulated to play amajor role in hepatic insulin clearance. Extrahepatic
tissues, such as kidneys, are also involved in insulin clearance in vivo, al-
beit to a lower extent than the liver [1]. However, IDE renal protein
levels were not induced in L-IDE-KO mice to compensate for the loss
of IDE in liver (Supplementary Fig. 9). Therefore, normoinsulinemia in
L-IDE-KO mouse rules out a major role for IDE in hepatic insulin clear-
ance. Consistently, Durham et al. demonstrated that NTE-1, an inhibitor
of IDE, did not increase plasma insulin levels in rodents [16].
By excluding IDE as a signiﬁcant mediator of insulin clearance
in vivo, we postulate that other proteins might be more critical in this
process. This could include CEACAM1, a substrate of the IR in liver
that, upon its phosphorylation, promotes the uptake of the insulin-
receptor complex and its targeting to the degradation process
[9,10,38]. Hepatic loss-of-function of CEACAM1 by overexpressing its
dominant-negative phosphorylation-defective isoform, reduced insulin
clearance to cause hyperinsulinemia followed by secondary insulin re-
sistance and impaired glucose tolerance [10]. CEACAM1 promotes insu-
lin clearance by inducing the rate of insulin endocytosis via the less
abundant, high-afﬁnity isoform A of the IR (IR-A) [33]. Upon itsphosphorylation on Tyr488 by the IR tyrosine kinase, via a mechanism
requiring insulin-stimulated phosphorylation of the IR at Tyr1316,
CEACAM1 recruits one or more molecules (including Shc) that bind to
Tyr960 of the juxtamembrane domain of the IR to form a stable complex
with the IR, and induce its uptake into clathrin-coated pits/vesicles [33].
Hence, CEACAM1phosphorylation is required but not sufﬁcient to allow
receptor-mediated insulin endocytosis and degradation [33].
Our results demonstrate that in the absence of hepatic IDE, IR phos-
phorylation is decreased, but that of CEACAM1 is disproportionally abro-
gated. Thus, it is plausible that IDE participates in the internalization of
the insulin-IR-CEACAM1 complex. Furthermore, hepatic depletion of IDE
remarkably reduced insulin-stimulated association between Shc and
CEACAM1, a critical step in the insulin's internalization process. It has
been proposed that IDE is a multifunctional protein, which may perform
unrelated functions as a scaffold protein involved in maintaining cellular
homeostasis [39]. Whether such a proposed function of IDE is dependent
on its protease activity, remains to be clariﬁed. If IDE deletion completely
blunts CEACAM1 phosphorylation (and function), one would question
how is circulating insulin being removed in L-IDE-KO mice? First,
CEACAM1 regulates insulin clearance by modulating insulin uptake via
the less abundant IR-A isoform in the liver. The contribution of the more
abundant IR-B isoform in insulin clearance in L-IDE-KO mice remains to
be elucidated. Second, at physiological concentrations of the hormone, he-
patic insulin clearance ismediated primarily by IR in the hepatocyte. How-
ever, the contribution of Kupffer cells to total insulin clearance in the liver
is ~15%. Thus, it is possible that these cells compensate for the loss of insu-
lin clearance in hepatocytes. Third,β-cell function andmass are similar be-
tween L-IDE-KOand controlmice, suggesting that plasma insulin levels are
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ciation from its receptor in the acidic environment of the endosomes, insu-
lin undergoes degradation whereas the receptor recycles to the plasma
membrane. Thus, in the absence of IDE, insulin is carried back to the circu-
lation bound to its receptor. Further research is needed to fully understand
the process of intact hepatic insulin clearance in the L-IDE-KO mouse.
On the other hand, we showed that Ide deletion resulted in a signif-
icant ~30% reduction of the IR in the plasma membrane of hepatocytes
from L-IDE-KO mice. Assuming that IDE does in fact degrade insulin in
endosomes, depletion of IDE in hepatocytes might impair the removal
of insulin and thereby impair the recycling of the IR to the cell surface.
This scenario is in agreement with the observed effects of hepatic IDE
depletion on plasma membrane IR levels in L-IDE-KO mice.
We herein demonstrate that ablation of hepatic Ide causes insulin re-
sistance independently of circulating insulin levels. Our results partially
coincide with those obtained by Farris et al. [12], and Abdul-Hay et al.
[11] that showed a marked insulin resistance with increased chronic
hyperinsulinemia in global IDE-KO mice. Systemic insulin resistance in
these mice was hypothesized to emerge as a secondary compensatory
response to chronic hyperinsulinemia. However, using the same IDE-
KO mice, Miller et al. [40] and Steneberg et al. [41], reported normal
plasma insulin levels in global IDE-KO mice. Nonetheless, our observa-
tions on L-IDE-KO mice suggest that the controversial systemic insulin
resistance and glucose intolerance exhibited by IDE-KO mice are at
least in part, a consequence of hepatic insulin resistance.
Whereas the liver-speciﬁc IR knockout mice (LIRKO) share with L-
IDE-KO mice elevated plasma glucose levels, glucose intolerance and
hepatic insulin resistance, they differ by developing chronic
hyperinsulinemia in part, resulting from a failure to clear circulating insu-
lin by receptor-mediated endocytosis [42,43]. This suggests that Ide deﬁ-
ciency per se causes insulin resistance and glucose intolerance
independently of hyperinsulinemia. From this point of view, our data
identify a role for IDE in themolecular pathwaysunderlininghepatic insu-
lin resistance, independently of their effect on glucagon, amylin andAβ40.
In summary, L-IDE-KOmiceprovides an in vivo evidence that the ab-
sence of hepatic IDE causes insulin resistance, higher blood glucose
levels, and glucose intolerance, through molecular mechanisms
involving impaired hepatic insulin signaling and upregulation of
gluconeogenic gene transcription. In agreement with previous studies
[16], this appears to occur via a mechanism that does not implicate its
role in hepatic insulin degradation. With the important caveat that
non-proteolytic functions of IDE might be operative in the observed
phenotype, these results suggest that pharmacological inhibition of
IDE are contraindicated in the treatment of type 2 diabetes.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.metabol.2018.08.001.
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